APD  Vol.6 No.1 , February 2017
Is Levodopa Pharmacokinetics in Patients with Parkinson’s Disease Depending on Gastric Emptying?
Abstract: Levodopa uptake from the gastrointestinal tract in patients with Parkinson’s disease (PD) can be affected by delayed gastric emptying (GE). This might lead to fluctuating levodopa levels resulting in increased motor fluctuations. Continuous dopaminergic stimulation (CDS) improves motor fluctuations and could be a result of smoothening in levodopa uptake. In this study we wanted to study the levodopa pharmacokinetics peripherally in PD patients with motor fluctuations and investigate the relation between levodopa uptake and GE and the effect of CDS. PD patients with wearing off (group 1) and on-off syndrome (group 2) were included. Breath tests were performed to evaluate the half time (T1/2) of GE. Concomitantly 1 tablet of Madopark&reg; was given and the levodopa concentrations in blood and subcutaneous (SC) tissue were analyzed for both groups. Group 2 was then given a 10-d continuous intravenous levodopa treatment and the tests were repeated. Higher levels of levodopa in group 1 compared to group 2 in blood (p = 0.014) were seen. The GE was delayed in both group 1 (p < 0.001) and group 2 (p < 0.05) compared to a reference group with healthy volunteers with T1/2 median values 105 and 78 min vs. 72 min. There was no difference in GE between the two PD groups (p = 0.220) or in group 2 before and after infusion period (p = 0.861). CDS resulted in lower levodopa levels in blood (p < 0.001) and SC tissue (p < 0.01). In conclusion, PD patients in early complication phase have a more favourable levodopa uptake than patients later in disease. We found delayed GE in PD patients with motor fluctuations but no obvious relation between GE and levodopa uptake or GE and PD stage. The effect of CDS indicates no effect of CDS on the mechanisms of GE but on the mechanisms of levodopa uptake.
Cite this paper: Nord, M. , Kullman, A. , Hannestad, U. and Dizdar, N. (2017) Is Levodopa Pharmacokinetics in Patients with Parkinson’s Disease Depending on Gastric Emptying?. Advances in Parkinson's Disease, 6, 1-12. doi: 10.4236/apd.2017.61001.

[1]   Khor, S.P. and Hsu, A. (2007) The Pharmacokinetics and Pharmacodynamics of Levodopa in the Treatment of Parkinson’s Disease. Current Clinical Pharmacology, 2, 234-243.

[2]   Nutt, J.G., Woodward, W.R., Hammerstad, J.P., Carter, J.H. and Anderson, J.L. (1984) The “On-Off” Phenomenon in Parkinson’s Disease. Relation to Levodopa Absorption and Transport. The New England Journal of Medicine, 310, 483-488.

[3]   Nyholm, D., Odin, P., Johansson, A., Chatamra, K., Locke, C., Dutta, S. and Othman, A.A. (2013) Pharmacokinetics of Levodopa, Carbidopa, and 3-O-Methyldopa Following 16-Hour Jejunal Infusion of Levodopa-Carbidopa Intestinal Gel in Advanced Parkinson’s Disease Patients. The AAPS Journal, 15, 316-323.

[4]   Djaldetti, R., Baron, J., Ziv, I. and Melamed, E. (1996) Gastric Emptying in Parkinson’s Disease: Patients with and without Response Fluctuations. Neurology, 46, 1051-1054.

[5]   Goetze, O., Nikodem, A.B., Wiezcorek, J., Banasch, M., Przuntek, H., Mueller, T., Schmidt, W.E. and Woitalla, D. (2006) Predictors of Gastric Emptying in Parkinson’s Disease. Neurogastroenterology and Motility, 18, 369-375.

[6]   Tanaka, Y., Kato, T., Nishida, H., Yamada, M., Koumura, A., Sakurai, T., Hayashi, Y., Kimura, A., Hozumi, I., Araki, H., Murase, M., Nagaki, M., Moriwaki, H. and Inuzuka, T. (2010) Is There a Delayed Gastric Emptying of Patients with Early-Stage, Untreated Parkinson’s Disease? An Analysis Using the (13)C-Acetate Breath Test. Journal of Neurology, 258, 421-426.

[7]   Muller, T., Erdmann, C., Bremen, D., Schmidt, W.E., Muhlack, S., Woitalla, D. and Goetze, O. (2006) Impact of Gastric Emptying on Levodopa Pharmacokinetics in Parkinson Disease Patients. Clinical Neuropharmacology, 29, 61-67.

[8]   Hardoff, R., Sula, M., Tamir, A., Soil, A., Front, A., Badarna, S., Honigman, S. and Giladi, N. (2001) Gastric Emptying Time and Gastric Motility in Patients with Parkinson’s Disease. Movement Disorders, 16, 1041-1047.

[9]   Marrinan, S., Emmanuel, A.V. and Burn, D.J. (2014) Delayed Gastric Emptying in Parkinson’s Disease. Movement Disorders, 29, 23-32.

[10]   Fasano, A., Bove, F., Gabrielli, M., Petracca, M., Zocco, M.A., Ragazzoni, E., Barbaro, F., Piano, C., Fortuna, S., Tortora, A., Di Giacopo, R., Campanale, M., Gigante, G., Lauritano, E.C., Navarra, P., Marconi, S., Gasbarrini, A. and Bentivoglio, A.R. (2013) The Role of Small Intestinal Bacterial Overgrowth in Parkinson’s Disease. Movement Disorders, 28, 1241-1249.

[11]   Mukherjee, A., Biswas, A. and Das, S.K. (2016) Gut Dysfunction in Parkinson’s Disease. World Journal of Gastroenterology, 22, 5742-5752.

[12]   Sung, H.Y., Park, J.W. and Kim, J.S. (2014) The Frequency and Severity of Gastrointestinal Symptoms in Patients with Early Parkinson’s Disease. Journal of Movement Disorders, 7, 7-12.

[13]   Pellegrini, C., Antonioli, L., Colucci, R., Ballabeni, V., Barocelli, E., Bernardini, N., Blandizzi, C. and Fornai, M. (2015) Gastric Motor Dysfunctions in Parkinson’s Disease: Current Pre-Clinical Evidence. Parkinsonism & Related Disorders, 21, 1407-1414.

[14]   Kurlan, R., Rothfield, K.P., Woodward, W.R., Nutt, J.G., Miller, C., Lichter, D. and Shoulson, I. (1988) Erratic Gastric Emptying of Levodopa May Cause “Random” Fluctuations of Parkinsonian Mobility. Neurology, 38, 419-421.

[15]   Deleu, D., Ebinger, G. and Michotte, Y. (1991) Clinical and Pharmacokinetic Comparison of Oral and Duodenal Delivery of Levodopa/Carbidopa in Patients with Parkinson’s Disease with a Fluctuating Response to Levodopa. European Journal of Clinical Pharmacology, 41, 453-458.

[16]   Doi, H., Sakakibara, R., Sato, M., Masaka, T., Kishi, M., Tateno, A., Tateno, F., Tsuyusaki, Y. and Takahashi, O. (2012) Plasma Levodopa Peak Delay and Impaired Gastric Emptying in Parkinson’s Disease. Journal of the Neurological Sciences, 319, 86-88.

[17]   Mouradian, M.M., Heuser, I.J., Baronti, F. and Chase, T.N. (1990) Modification of Central Dopaminergic Mechanisms by Continuous Levodopa Therapy for Advanced Parkinson’s Disease. Annals of Neurology, 27, 18-23.

[18]   Stocchi, F., Ruggieri, S., Vacca, L. and Olanow, C.W. (2002) Prospective Randomized Trial of Lisuride Infusion versus Oral Levodopa in Patients with Parkinson’s Disease. Brain, 125, 2058-2066.

[19]   Stocchi, F., Vacca, L., Ruggieri, S. and Olanow, C.W. (2005) Intermittent vs Continuous Levodopa Administration in Patients with Advanced Parkinson Disease: A Clinical and Pharmacokinetic Study. Archives of Neurology, 62, 905-910.

[20]   Timpka, J., Mundt-Petersen, U. and Odin, P. (2016) Continuous Dopaminergic Stimulation Therapy for Parkinson’s Disease—Recent Advances. Current Opinion in Neurology, 29, 474-479.

[21]   Honig, H., Antonini, A., Martinez-Martin, P., Forgacs, I., Faye, G.C., Fox, T., Fox, K., Mancini, F., Canesi, M., Odin, P. and Chaudhuri, K.R. (2009) Intrajejunal Levodopa Infusion in Parkinson’s Disease: A Pilot Multicenter Study of Effects on Nonmotor Symptoms and Quality of Life. Movement Disorders, 24, 1468-1474.

[22]   Reddy, P., Martinez-Martin, P., Rizos, A., Martin, A., Faye, G.C., Forgacs, I., Odin, P., Antonini, A. and Chaudhuri, K.R. (2012) Intrajejunal Levodopa versus Conventional Therapy in Parkinson Disease: Motor and Nonmotor Effects. Clinical Neuropharmacology, 35, 205-207.

[23]   Dizdar, N., Granerus, A.K., Hannestad, U., Kullman, A., Ljungdahl, A., Olsson, J.E. and Kagedal, B. (1999) L-Dopa Pharmacokinetics Studied with Microdialysis in Patients with Parkinson’s Disease and a History of Malignant Melanoma.. Acta Neurologica Scandinavica, 100, 231-237.

[24]   Ungerstedt, U. (1991) Microdialysis—Principles and Applications for Studies in Animals and Man. Journal of Internal Medicine, 230, 365-373.

[25]   Meyerhoff, C., Bischof, F., Mennel, F.J., Sternberg, F. and Pfeiffer, E.F. (1993) Use of the Microdialysis Technique in the Monitoring of Subcutaneous Tissue Glucose Concentration. The International journal of Artificial Organs, 16, 268-275.

[26]   Paez, X. and Hernandez, L. (1997) Blood Microdialysis in Humans: A New Method for Monitoring Plasma Compounds. Life Sciences, 61, 847-856.

[27]   Dizdar, N., Kullman, A., Norlander, B., Olsson, J.E. and Kagedal, B. (1999) Human Pharmacokinetics of L-3,4-Dihydroxyphenylalanine Studied with Microdialysis. Clinical Chemistry, 45, 1813-1820.

[28]   Ghoos, Y.F., Maes, B.D., Geypens, B.J., Mys, G., Hiele, M.I., Rutgeerts, P.J. and Vantrappen, G. (1993) Measurement of Gastric Emptying Rate of Solids by Means of a Carbon-Labeled Octanoic Acid Breath Test. Gastroenterology, 104, 1640-1647.

[29]   Goetze, O., Wieczorek, J., Mueller, T., Przuntek, H., Schmidt, W.E. and Woitalla, D. (2005) Impaired Gastric Emptying of a Solid Test Meal in Patients with Parkinson’s Disease Using 13C-Sodium Octanoate Breath Test. Neuroscience Letters, 375, 170-173.

[30]   Meier, J.J., Gallwitz, B., Salmen, S., Goetze, O., Holst, J.J., Schmidt, W.E. and Nauck, M.A. (2003) Normalization of Glucose Concentrations and Deceleration of Gastric Emptying after Solid Meals during Intravenous Glucagon-Like Peptide 1 in Patients with Type 2 Diabetes. The Journal of Clinical Endocrinology and Metabolism, 88, 2719-2725.

[31]   O’Connell, M.T., Tison, F., Quinn, N.P. and Patsalos, P.N. (1996) Clinical Drug Monitoring by Microdialysis: Application to Levodopa Therapy in Parkinson’s Disease. British Journal of Clinical Pharmacology, 42, 765-769.

[32]   Krygowska-Wajs, A., Cheshire Jr., W.P., Wszolek, Z.K., Hubalewska-Dydejczyk, A., Jasinska-Myga, B., Farrer, M.J., Moskala, M. and Sowa-Staszczak, A. (2009) Evaluation of Gastric Emptying in Familial and Sporadic Parkinson Disease. Parkinsonism & Related Disorders, 15, 692-696.

[33]   Contin, M. and Martinelli, P. (2010) Pharmacokinetics of Levodopa. Journal of Neurology, 257, S253-S261.

[34]   Lennernas, H., Nilsson, D., Aquilonius, S.M., Ahrenstedt, O., Knutson, L. and Paalzow, L.K. (1993) The Effect of L-Leucine on the Absorption of Levodopa, Studied by Regional Jejunal Perfusion in Man. British Journal of Clinical Pharmacology, 35, 243-250.

[35]   Murata, M. and Kanazawa, I. (1993) Repeated L-Dopa Administration Reduces the Ability of Dopamine Storage and Abolishes the Supersensitivity of Dopamine Receptors in the Striatum of Intact Rat. Neuroscience Research, 16, 15-23.

[36]   Murata, M., Mizusawa, H., Yamanouchi, H. and Kanazawa, I. (1996) Chronic Levodopa Therapy Enhances Dopa Absorption: Contribution to Wearing-Off. Journal of Neural Transmission, 103, 1177-1785.

[37]   Robertson, D.R., Wood, N.D., Everest, H., Monks, K., Waller, D.G., Renwick, A.G. and George, C.F. (1989) The Effect of Age on the Pharmacokinetics of Levodopa Administered Alone and in the Presence of Carbidopa. British Journal of Clinical Pharmacology, 28, 61-69.

[38]   Iwamoto, K., Watanabe, J. and Atsumi, F. (1987) Age Dependence in Capacity-Limited Jejunal Decarboxylation of Levodopa in Rats. Biochemical Pharmacology, 36, 2151-2155.

[39]   Zsigmond, P., Dernroth, N., Kullman, A., Augustinsson, L.E. and Dizdar, N. (2012) Stereotactic Microdialysis of the Basal Ganglia in Parkinson’s Disease. Journal of Neuroscience Methods, 207, 17-22.

[40]   Krygowska-Wajs, A., Lorens, K., Thor, P., Szczudlik, A. and Konturek, S. (2000) Gastric Electromechanical Dysfunction in Parkinson’s Disease. Functional Neurology, 15, 41-46.

[41]   Soykan, I., Lin, Z., Bennett, J.P. and McCallum, R.W. (1999) Gastric Myoelectrical Activity in Patients with Parkinson’s Disease: Evidence of a Primary Gastric Abnormality. Digestive Diseases and Sciences, 44, 927-931.